Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen's Sensipar EVOLVE trial misses goal on CV outcomes benefit

This article was originally published in Scrip

Executive Summary

Amgen has suffered a setback in its bid to add a cardiovascular outcomes benefit to its oral calcimimetic agent, cinacalcet (Sensipar in the US; Mimpara outside the US). In announcing top-line results from its Phase III EVOLVE trial, the company said the trial did not meet its endpoint. The drug is already approved to treat secondary hyperparathyroidism in patients with chronic kidney disease receiving dialysis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts